Patient-specific factors associated with use of diabetes self-management education and support programs in Louisiana.

INTRODUCTION: The prevalence of diabetes self-management education and support (DSME/S) use among patients with newly diagnosed type 2 diabetes mellitus (T2DM) and patients with insulin prescription has not been evaluated. It is also unclear what demographic, behavioral, and clinical factors associated with use of DSME/S. RESEARCH DESIGN AND METHODS: This retrospective analysis was based on electronic health records from the Research Action for Health Network (2013-2019). Patients with newly diagnosed T2DM were identified as 35-94 year-olds diagnosed with T2DM≥1 year after the first recorded office visit. Patients with insulin were identified by the first insulin prescription records. DSME/S (Healthcare Common Procedure Coding System G0108 and G0109) codes that occurred from 2 months before the 'new diagnosis date' or first insulin prescription date through 1 year after were defined as use of DSME/S. Age-matched controls (non-users) were identified from the Electronic Health Records (EHR). The date of first DSME/S record was selected as the index date. Logistic regression was used to estimate the associations between patient factors and use of DSME/S.
RESULTS: The prevalence of DSME/S use was 6.5% (8909/137 629) among patients with newly diagnosed T2DM and 32.7% (13,152/40,212) among patients with diabetes taking insulin. Multivariable analysis found that among patients with newly diagnosed T2DM, black and male patients were less likely to use DSME/S, while in patients with insulin, they were more likely to use the service compared with white and female counterparts, respectively. Among patients taking insulin, those with private insurance or self-pay status were significantly less likely, while those with Medicaid were more likely to use the service compared with their Medicare counterparts. A strong positive association was found between HbA1c, obesity, and DSME/S use in both cohorts, while hypertension was negatively associated with DSME/S in both cohorts.
CONCLUSION: We showed a low rate of DSME/S use in Louisiana, especially in patients with newly diagnosed T2DM. Our findings demonstrated heterogeneity in factors influencing DSME/S use between patients with newly diagnosed T2D and patients with insulin. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Diabetes self-management education and support (DSME/S) is underused despite its efficacy in improving clinical, psychosocial, and behavioral outcomes demonstrated in trials and its service coverage by most health plans.

Previous data suggest that there is a large gap between the recommended guideline and current practice, and that there is both an opportunity and a need to enhance rates of DSME/S participation among patients with diabetes.

There was a low rate of DSME/S use in Louisiana, especially in patients with newly diagnosed type 2 diabetes mellitus (T2DM).

Among patients with newly diagnosed T2DM, black and male patients were less likely to use DSME/S, while in patients taking insulin, they were more likely to use DSME/S compared with white and female counterparts, respectively.

Insurance status appeared to play a role in using DSME/S among patients taking insulin. A strong positive association was found between HbA1c, obesity, and DSME/S use in both cohorts, while hypertension was negatively associated with DSME/S in both cohorts.

There were significant variations in factors associated with DSME/S use in two patient cohorts representing the initial and advanced stage of diabetes, respectively.

Factors identified by this study can be used to reduce barriers to DSME/S access, coordinate existing services, and develop new methods of service delivery for patients with newly diagnosed T2DM or those undergoing insulin treatments.

Background

Type 2 diabetes mellitus (T2DM) is a manageable chronic condition that affects 34.2 million people in the USA.1 Louisiana has the fourth highest diabetes prevalence in the nation (14% in the state vs 10.9% nationally in 2019), with the vast majority being T2DM.2 Diabetes self-management is a necessary component of diabetes care and plays an important role in glycemic outcome management and preventing or delaying diabetes-related complications when administered alongside medical care and management.3 Diabetes self-management education and support (DSME/S) is a comprehensive educational program designed to help people with diabetes navigate complex self-management decisions and activities.4 The primary goals of DSME/S programs are to enhance diabetes self-care knowledge, skills training, learning how to overcome identified barriers, and to create self-efficacy.4 The American Diabetes Association (ADA) and the Association of Diabetes Care & Education Specialists endorse the National Standards for DSME/S to promote quality education for this patient group. The ADA recommends that all individuals with diabetes receive DSME/S at diagnosis and as needed thereafter.4 The time immediately following diagnosis represents a critical window when patients are seeking information about their new condition and are likely to be overwhelmed by the many behavioral changes they are asked to adopt.5 The importance of DSME/S continues beyond the initial diagnosis.4 Receiving education at critical times during the disease progression, such as when new medication or treatment is needed, can help patients cope with new challenges, learn how to administer, and follow new self-care regimens, and appropriately adjust meal plans and physical activity levels to maximize health outcomes and quality of life.4

DSME/S is underused despite its efficacy in improving clinical, psychosocial, and behavioral outcomes demonstrated in trials and its service coverage by most health plans.6–8 Reimbursement for DSME/S is available from the Centers for Medicare and Medicaid Services and many private payers.4 However, only 6.8% of individuals with newly diagnosed T2DM with private health insurance participated in DSME/S within 12 months of diagnosis.7 Only 4% of Medicare beneficiaries received DSME/S.8 Even among patients who attend DSME/S classes, attrition rates are often high.9 These data suggest there is a large gap between the recommended guideline and current practice, and that there is both an opportunity and a need to enhance rates of DSME/S participation among patients with diabetes.7

An increasing number of studies have examined barriers that contribute to the underuse and attrition of DSME/S. Known barriers include competing priorities, transportation difficulties, forgetfulness, apathy, low perceived seriousness of diabetes, and lack of accessible services.10–12 Many previous studies relied on self-reported data that did not necessarily consider the time of diagnosis of a patient, disease risk factors, and sociodemographic backgrounds. Given that patients may encounter different challenges at different stages of the disease, evaluating factors influencing DSME/S usage for the portion of newly diagnosed and those at disease and treatment transitions separately is necessary. The objectives of the study include (1) assessing the prevalence of receiving DSME/S among patients with newly diagnosed T2DM and patients who have undergone insulin treatments and (2) examining demographic, behavioral, and clinical factors associated with use of DSME/S in these two cohorts.

Methods

Data source

This retrospective cross-sectional analysis is based on data from patients with T2DM in the LEAD cohort study (Louisiana Experiment Assessing Diabetes outcomes). The patient records were obtained through the Research Action for Health Network (REACHnet) from three partner health systems in Louisiana between January 1, 2013 and October 10, 2019.

Sample and case definitions

We first identified 35–94-year-old patients with T2DM. T2DM was defined by the Surveillance, Prevention, and Management of Diabetes Mellitus (SUPREME-DM) algorithms,13 that is meeting any of the following criteria: (1) one or more of the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes and Tenth Revision, Clinical Modification (ICD-10-CM) codes for T2DM associated with in-patient encounters; (2) two or more ICD codes associated with outpatient encounters on different days within 2 years; (3) combination of two or more of the following associated with outpatient encounters on different days within 2 years: (1) ICD codes; (2) fasting glucose level ≥126 mg/dL; (3) 2-hour glucose level ≥200 mg/dL; (4) random glucose ≥200 mg/dL; (5) hemoglobin A1c (HbA1c)≥6.5%; and (6) prescription for an glucose-lowering medication.14 A total of 331 242 patients with T2DM were identified.

New T2DM cases were defined as entry of T2DM diagnosis in the clinical record ≥1 year after the first recorded office visit (n=137 629). Patients taking insulin were identified by first insulin prescription records in the Electronic Health Records (EHR) (n=40 212). DSME/S (Healthcare Common Procedure Coding System (HCPCS) codes G0108 and G0109) codes that occurred between 2 months before the ‘new diagnosis date’ or first insulin prescription date through 1 year after were defined as use of DSME/S service. After applying all criteria, a cohort of newly diagnosed cases included a total of 8909 DSME/S users and a cohort of patients taking insulin included a total of 3572 DSME/S users, respectively. Age-matched non-DSME/S users were also identified in the same study period. We adopted the gmatch macro in SAS that used the greedy matching algorithm with one non-user per user.15 The date of first DSME/S record was selected as index date. For comparison, an index date was assigned as their matched DSME/S users.

Measures

The primary outcome was DSME/S use 2 months prior or within 1 year of the first diagnosed date or the first insulin prescription. Demographic variables included the following: age at diagnosis, sex, race, insurance type, and smoking status. Clinical or biomarkers included HbA1c, low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol, triglycerides, blood pressure, and body mass index (BMI). These were average values of available lab or examination records in the study period. Medication use was measured by any prescription records of glucose-lowering, blood pressure-lowering, or lipid-lowering medications in the database.

Analysis

T-tests and χ² tests were performed to compare differences between DSME/S and non-DSME/S groups≥180 days before the first recorded DSME/S (baseline) in the two cohorts, respectively. Multivariable logistic regression was used to estimate the independent effects of these baseline characteristics on DSME/S attendance. Covariates adjusted in multivariable model included age at diagnosis, sex, race, insurance type, smoking status, HbA1c, LDL, HDL, total cholesterol, triglycerides, blood pressure, BMI, glucose-lowering, blood pressure-lowering, and lipid-lowering medications. All analyses were performed using SAS V.9.2 (Cary, North Carolina, USA).

The study and analysis plan were approved by Tulane University Institutional Review Board (IRB number: 2019–1572). We used a limited dataset, as defined by HIPAA, abstracted from medical records that does not contain personally identifiable information except date of birth. The IRB granted a waiver of informed consent.

Results

The prevalence of initial DSME/S use among patients within the first year of diagnosis was 6.5% (8909/137 629) in the study period. In patients taking insulin, the prevalence of any DSME/S use (ie, initial or follow-up sessions) was 32.7% (13 152/40 212). In insulin user group, 3572 patients attended DSME/S for the first time. Compared with the age-matched non-DSME/S group, the DSME/S group had higher mean HbA1c (8.7 vs 6.9 and 9.4 vs 7.9 in newly diagnosed and patients with insulin cohort, respectively) and triglycerides (174.8 vs 137.8 mg/dL and 183.1 vs 169.2 mg/dL in two cohorts, respectively), and higher prevalence of obesity (47.4 vs 31.3% and 46.2 vs 35.9%) in both newly diagnosed patients and patients with insulin cohorts. In both cohorts, DSME/S group had fewer white patients (56.5 vs 65.3% and 50.4 vs 58%, respectively), fewer current smokers (7.7 vs 15.9% and 8.6 vs 12.1%, respectively), but more patients with Medicare or private insurance than their counterparts in the non-DSME/S group (94.4 vs 92% and 95.4 vs 89.3%, respectively). In patients with insulin, more black patients were found in DSME/S compared with non-DSME/S group (48.1 vs 40.8%, respectively). Fewer male patients were found in DSME/S than in non-DSME/S group (44.6 vs 49.6%, respectively). In both cohorts, patients in DSME/S group had higher frequencies of taking any lipid-lowering drugs (51.9 vs 44.1% and 46.3 vs 38.2%, respectively) or oral glucose-lowering drugs (84.5 vs 33.7% and 93 vs 69.5%, respectively) but had less frequencies of taking any blood pressure-lowering drugs (71.9 vs 80.3% and 65.7 vs 68.2%, respectively) (table 1).

Table 1

Demographic, behavioral, and clinical characteristics of patients with newly diagnosed T2DM and patients with insulin by DSME/S in Louisiana

	New T2DM cohort (n=17 918)			Patients with insulin cohort (n=7144)
	DSME/S group (n=8909)	Age-matched non-DSME/S group (n=8909)	P value	DSME/S group (n=3572)	Age-matched non-DSME/S group (n=3572)	P value
Age (mean, SD)	66	66	1.0	66	66	1.0
Race, %			<0.0001			<0.0001
White	56.5	65.3		50.4	58.0
Black	42.4	43.6		48.1	40.8
Others	1.1	1.9		1.5	1.2
Males, %	45.1	45.2	0.91	44.6	49.6	<0.0001
Insurance type, %			<0.0001			<0.0001
Private	33.3	31.8		32.5	25.9
Medicare	61.1	60.2		61.9	63.4
Medicaid	2.1	3.7		2.1	6.5
Self-pay	0.5	1.3		0.4	1.5
Unknown	3.0	3.0		3.1	2.7
Tobacco use, %			<0.0001			<0.0001
Current smoker	7.7	15.9		8.6	12.1
Never smoker	82.4	70.3		80.1	78.6
Quit/former smoker	9.9	13.8		11.4	9.4
Medications
Lipid-lowering drugs, %	51.9	44.1	<0.0001	46.3	38.2	<0.0001
Oral glucose-lowering drugs, %	84.5	33.7	<0.0001	93.0	69.5	<0.0001
Blood pressure-lowering drugs, %	71.9	80.3	<0.0001	65.7	68.2	0.07
Clinical or biomarkers
HbA1c (%), mean (SD)	8.7 (2.1)	6.9 (1.5)	<0.0001	9.4 (2.3)	7.9 (2.0)	<0.0001
Blood pressure, mm Hg, mean (SD)
Systolic	133.7 (17.7)	133.4 (19.3)	0.58	133.7 (17.7)	133.4 (19.3)	0.58
Diastolic	76.5 (10.7)	76.3 (11.3)	0.43	76.5 (10.7)	76.3 (10.3)	0.42
Total cholesterol, mg/dL, mean	178.3 (47.9)	176.8 (42.3)	0.22	178.0 (56.4)	168.8 (53.0)	<0.0001
LDL cholesterol, mg/dL, mean (SD)	102.3 (37.2)	102.6 (34.5)	0.74	100.0 (40.7)	93.4 (38.3)	<0.0001
HDL cholesterol, mg/dL, mean (SD)	43.2 (12.2)	47.3 (14.0)	<0.0001	43.2 (13.3)	43.2 (14.0)	0.99
Triglycerides, mg/dL, mean (SD)	174.8 (182.4)	137.8 (103.8)	<0.0001	183.1 (220.4)	169.2 (231.6)	0.11
Obesity (BMI >30), %	47.4	31.3	<0.0001	46.2	35.9	<0.0001

BMI, body mass index; DSME/S, diabetes self-management education and support programs; HDL, high-density lipoprotein; LDL, low-density lipoprotein; T2DM, type 2 diabetes mellitus.

Results from multivariable logistic regressions showed that among patients with newly diagnosed T2DM, black and other minority patients were less likely to use DSME/S compared with their white counterparts (OR 0.42, 95% CI 0.35 to 0.51 and OR 0.1, 0.05 to 0.16, in black and other minority group, respectively), and male patients were more likely to use DSME/S than their female counterparts (1.63, 1.34 to 1.97). In contrast, among patients taking insulin, black were more likely to use DSME/S than their white counterparts (3.54, 3.01 to 4.16), and male patients (1.15, 0.99 to 1.32) were less likely to use the service than their female counterparts. Among patients with insulin, those with private insurance or self-pay status were significantly less likely (0.8, 0.69 to 0.93 and 0.33, 0.16 to 0.7, in private insurance and self-pay group, respectively), while patients with Medicaid were more likely (3.4, 1.08 to 10.68) to use the service compared with their Medicare counterparts. Patients who were current or former smokers were less likely to use DSME/S in newly diagnosed patients (0.43, 0.41 to 0.45 and 0.56, 0.54 to 0.58 in current and former smokers, respectively). Those with elevated HbA1c levels had more than a fivefold likelihood of receiving DSME/S compared with individuals with HbA1c within target range in the newly diagnosed T2DM cohort (5.4, 4.24 to 6.88). A strong positive association was also found between obesity status (3.97, 3.11 to 5.07 and 3.23, 2.68 to 3.88, in two cohorts, respectively) and DSME/S use in both cohorts; hypertension (0.62, 0.48 to 0.81 and 0.69, 0.56 to 0.84 in two cohorts, respectively), however, was negatively associated with DSME/S. In both cohorts, patients with any oral glucose-lowering medications were more likely to use DSME/S (1.78, 1.46 to 2.17 and 3.5, 3.04 to 4.03 in two cohorts, respectively), but patients with any blood pressure-lowering drugs (0.6, 0.45 to 0.8 and 1.32, 1.14 to 1.53 in two cohorts, respectively) were less likely to use DSME/S than those without the medications. Any use of lipid-lowering medications was negatively associated with use of DSME/S in newly diagnosed patients (0.41, 0.33 to 0.5) (table 2).

Table 2

Results from logistic regression for factors associated with DSME/S use among patients with newly diagnosed T2DM and patients with insulin in Louisiana

	New T2DM cohort (n=17 918)		Patients with insulin cohort (n=7144)
	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)
Race
White (ref.)	1	1
Black	0.99 (0.95 to 1.03)	0.42 (0.35 to 0.51)*	1.35 (1.32 to 1.39)**	3.54 (3.01 to 4.16)**
Others	0.71 (0.61 to 0.84)**	0.10 (0.05 to 0.16)**	1.44 (1.31 to 1.59)**	0.13 (0.10 to 0.16)**
Sex
Female (ref.)	1	1	1	1
Male	0.99 (0.95 to 1.02)	1.63 (1.34 to 1.97)**	0.76 (0.74 to 0.77)**	1.15 (0.99 to 1.32)
Insurance
Medicare (ref.)	1	1	1	1
Medicaid	0.59 (0.51 to 0.58)**	1.97 (0.63 to 6.22)	0.33 (0.31 to 0.35)**	3.40 (1.08 to 10.68)**
Private	1.03 (1.00 to 1.06)**	1.09 (0.89 to 1.33)	1.28 (1.25 to 1.32)**	0.80 (0.69 to 0.93)**
Self-pay and unknown	0.39 (0.34 to 0.44)**	2.62 (0.36 to 18.96)	0.25 (0.21 to 0.29)**	0.33 (0.16 to 0.70)**
Smoking
Never (ref.)	1	1	1	1
Current	0.43 (0.41 to 0.45)**	0.32 (0.23 to 0.44)**	0.70 (0.61 to 0.80)**	1.34 (0.95 to 1.89)
Former	0.56 (0.54 to 0.58)**	0.34 (0.26 to 0.43)**	1.20 (1.03 to 1.40)**	1.29 (1.00 to 1.63)*
Medications
Lipid-lowering drugs
No, ref.	1	1	1	1
Yes	1.39 (1.35 to 1.43)**	0.41 (0.33 to 0.50)**	1.91 (1.86 to 1.96)**	0.97 (0.84 to 1.11)
Oral glucose-lowering drugs
No, ref.	1	1	1	1
Yes	11.56 (11.20 to 11.93)**	1.78 (1.46 to 2.17)*	4.96 (4.82 to 5.11)**	3.50 (3.04 to 4.03)**
Blood pressure-lowering drugs
No, ref.	1	1	1	1
Yes	0.65 (0.63 to 0.67)**	0.60 (0.45 to 0.80)*	0.79 (0.77 to 0.82)**	1.32 (1.14 to 1.53)*
Clinical risks
Elevated HbA1c (>7%)
No, ref	1	1	1	1
Yes	8.95 (8.61 to 9.31)**	5.40 (4.24 to 6.88)**	5.11 (4.96 to 5.27)**	1.34 (1.14 to 1.53)**
Elevated blood pressure (SBP >130/DBP>80 mm Hg)
No, ref	1	1	1	1
Yes	0.28 (0.27 to 0.29)**	0.62 (0.48 to 0.81)**	0.40 (0.37 to 0.43)**	0.69 (0.56 to 0.84)**
Elevated total cholesterol (>200 mg/dL)
No, ref.	1	1	1	1
Yes	1.04 (0.99 to 1.08)	1.25 (0.98 to 1.58)	1.29 (1.24 to 1.34)**	0.96 (0.80 to 1.16)
Obesity (BMI >30)
No, ref.	1	1	1	1
Yes	2.22 (2.17 to 2.28)**	3.97 (3.11 to 5.07)**	1.88 (1.74 to 2.03)**	3.23 (2.68 to 3.88)**

*<0.05; **<0.0001. Adjusted model included all variables listed in the table.

BMI, body mass index; DBP, distolic blood pressure; DSME/S, diabetes self-management education and support programs; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus.

Discussion

Our results showed a low rate of DSME/S use in Louisiana, especially in patients with newly diagnosed T2DM. Our findings also demonstrated heterogeneity in patient-specific factors that influence use of DSME/S patients with among newly diagnosed T2DM and patients who have undergone insulin treatments. The patient-cohort stratification is important as people with T2DM face different challenges in self-management decisions and tasks at different stages of their disease. First, we found that black patients who had been prescribed insulin were more likely to use DSME/S than their white counterparts, which appears to be contradictory to the previous thinking that blacks were less likely to commit to self-management activities for their chronic conditions as a result of a variety of biopsychosocial and sociocultural factors.16 Some research suggested that those who initiated insulin treatments had higher rates of self-care, such as following a healthier diet and engaging in self-monitoring of blood glucose, than those who did not use insulin.17 18 In race-stratified analyses, two studies have demonstrated that current black patients with insulin prescription who face a higher risk for diabetes-related morbidity and mortality are prone to engage in higher levels of diabetes-specific self-monitoring (blood glucose and foot care) than their white counterparts.19 20 This is consistent with our finding, indicating greater needs and perhaps, higher motivation to manage the health conditions among black patients with insulin prescription.

Additionally, we found an interesting sex difference in receiving DSME/S, especially in the newly diagnosed T2DM patient cohort. It is often thought that women are prone to use socially interactive resources, like education classes and support groups, whereas men rely more on self-directed learning.21–23 Yet, previous research regarding the sex difference in receiving DSME/S did not show women had a significantly higher rates in participating in the service.17 24 Our finding showed that among patients with newly diagnosed T2DM, men were significantly more likely to use DSME/S compared with women. There were data showing men expressed significantly greater need for information on primary prevention issues and unhealthy health practices, such as smoking.25 Data from the Health and Retirement Study also indicated that women were less likely to use preventive care including influenza shot or cholesterol screening, to have hospital stays, and to have fewer physician visits than men with similar health profiles.26 Compared with men, women with healthcare problems may be more isolated or have more caregiving responsibility, limiting their ability to obtain medical services.26 27 Additionally, women are less likely than men to be insured through their own job and more likely to be covered as a dependent, and more often cite financial and transportation barriers to accessing healthcare and treatment.28 All these factors are likely to explain the sex difference in receiving DSME/s seen in our study.

Further, we identified a differential role of smoking status in receiving DSME/S by patient cohort. Consistent with previous findings, our data showed that smokers were significantly less likely to use DSME/S in patients with newly diagnosed T2DM,10 23 29 while in patients with more advanced diabetes (ie, those with insulin), smoking, especially former smoking status, was positively associated with use of DSME/S. This scenario may be explained by a ‘healthy smoker’ effect (where sick smokers selectively quit smoking and seeking healthcare and advice at greater rates than healthy smokers).30 Several studies found smokers were less likely to use primary care or preventive services compared with non-smokers. This may be due to an optimistic bias in relation to smoking, such that smokers tend to see the risks of smoking as lower for themselves than for others.30–32 Fewer smokers than ex-smokers accept that smoking causes disease, and smokers also maintain beliefs that exempt them from personalizing widespread acceptance that smoking harms health.33 Such attitudes might translate into denial of other health risks (such as diabetes related complications) and delay in seeking disease management skills. On the contrary, ‘sick smokers’ such that who have longer diabetes history (ie, those with insulin) tend to ‘look after themselves’ by seeking more healthcare and services.

Uninsured status has been identified as a barrier to accessing and attending health education sessions.34 However, there are limited data examining payer type and DSME/S use.7 10 29 In our study, we found among patients with insulin, those with self-pay or private insurance status were significantly less likely to attend the service compared with Medicare beneficiaries. Some patients with diabetes may already struggle with the equipment and supplies necessary to manage their diabetes; the added cost of paying for DSME/S out of pocket, either because the patient does not have insurance or due to insurance cost-sharing requirements, could be a barrier to participation.7 10 29 Additionally, we found patients with insulin with Medicaid were more likely to use the service compared with their Medicare counterparts. Relative to the Medicare group, Medicaid patients are generally younger, have fewer comorbidities,35 and do not need to obtain a referral from the healthcare professional treating their diabetes to receive the service coverage.36 All these factors may contribute to the higher likelihood of DSME/S in Medicaid relative to Medicare patients that found in this study.

Among clinical factors, elevated HbA1c at baseline was significantly associated with use of DSME/S, especially in newly diagnosed patients. In a similar vein, patients with any glucose-lowering medication also had significantly higher odds of DSME/S use, which appears to reflect the same pattern that people with high demand on glycemic outcome management are more likely to take advantage of DSME/S. Additionally, in both newly diagnosed patients and those with insulin, hypertension was negatively associated with use of DSMES/S, which is in line with previous research.37 Compared with elevated HbA1c, hypertension did not appear to motivate patients to seek self-management skills in our study. Reasons for the lower DSME/S use among hypertensive patients with T2DM are not clear but may be due to the low awareness of severe consequences of hypertension in diabetes and the importance of blood pressure management.38–40 Findings from clinic-based and population-based surveys have shown that only 13%–40% of patients with diabetes achieved optimal blood pressure targets,38–40 and one study found fewer than half of patients with hypertension were aware of the importance of blood pressure management.41 One important component of DSME/S is to educate patients with health monitoring, including blood pressure monitoring. Our findings further indicate the needs to promote DSME/S among patients with T2DM, especially among those with uncontrolled blood pressure. Moreover, we found obesity was associated with more than threefold higher odds of DSME/S use in both patient cohorts. More than half of adults with diabetes are obese,42 and the first few months postdiagnosis is a key window during which patients with diabetes may actively seek and apply weight-loss interventions.43 What makes weight control challenging in T2DM is that many pharmacological agents including insulin directly contribute to weight gain through their glucose-lowering mechanisms.44 45 Also, patients engaging in lifestyle interventions who initially lost weight may encounter a plateau in weight loss, generally followed by a weight regain.46 Weight management is a long-term task for patients with T2DM, which is a plausible reason for the higher likelihood of DSME/S use among obese patients in both our patient cohorts.

Limitations and strengths

This is the first study to examine the demographic, behavioral, and clinical factors that are associated with DSME/S use in Louisiana, where the T2DM rate is persistently higher than the national level and diabetes education is critically needed.2 There are several limitations to be acknowledged. First, this is a cross-sectional analysis which limits the ability to make temporal or causal inferences. Second, we used the HCPCS codes to identify use of DSME/S, which is not equivalent to the actual completion or commitment of DSME/S, and those without HCPCS codes (ie, non-users) possibly had been referred to but did not attend the service. However, HCPCS codes are the best proxy available to identify those with or without exposure to DSME/S. Additionally, the SUPREME-DM algorisms cannot distinguish members with type 1 diabetes (T1DM) and T2DM with a high level of precision. However, SUPREME-DM is the gold standard algorisms to identify non-T1DM adults, that is, for adults with T2DM and DM of uncertain and rare types.47 Further, medication records used in the analysis were based on prescription records from providers. Dispensing data were not available for this analysis. We also acknowledged that smoking status/tobacco use in EHR is notoriously inaccurate or not routinely updated. Since the accuracy of smoking status could not be confirmed for this observational analysis, we caution the interpretation of the relationship between smoking status and DSME/S use. Moreover, the association between ‘Other race/ethnicity’, ‘Medicaid’ or ‘Private insurance’, and use of the DSME/S should also be interpreted with caution. These covariate categories are small in counts. In multivariable logistic regression, the logit coefficients of these variables may suffer from small sample bias, which potentially leads to overestimation or underestimation. With these limitations being noted, the patient-specific factors identified from the study may be more modifiable in enhancing DSME/S use compared with removing barriers in clinics, healthcare system or environment. Last, we did not include healthcare providers’ characteristics or healthcare system barriers that also influence patients’ access and utilization of DSME/S. Additionally, the study assessed a large population of patients in routine clinical care in Louisiana; the results are therefore more generalizable than those from single-centered clinical trials with selective inclusion criteria.

Conclusion

Our study demonstrated a low rate of DSME/S in Louisiana. We also uncovered significant variations in factors associated with DSME/S use in two patient cohorts representing the initial and advanced stage of diabetes, respectively. Knowledge about the patient-specific barriers to receiving DSME/S is the first step in improving DSME/S uptake. Factors identified by this study can be used to reduce barriers to DSME/S access, coordinate existing services, and develop new methods of service delivery for patients with newly diagnosed T2DM or those undergoing insulin treatments.